Higher baseline absolute monocyte counts, largely reflecting classical CD16–CD14+ monocytes, have been identified as predictors of a better antidepressant response during intravenous ketamine treatment for individuals with treatment-resistant depression. The gene discussed is CD14; the disease is depressive symptom measurement.